OBJECTIVES: Chronic hepatitis B (CHB) is a condition that results in substantial morbidity and mortality worldwide because of progressive liver damage. Investigators undertaking economic evaluations of new therapeutic agents require estimates of health-related quality of life (HRQOL). Recently, evidence has begun to accumulate that differences in cultural backgrounds have a quantifiable impact on perceptions of health. The objective was to elicit utilities for six health states that occur after infection with the hepatitis B virus from infected and uninfected respondents living in jurisdictions with low and with high CHB endemicity. METHODS: Standard gamble utilities were elicited from hepatitis patients and uninfected respondents using an interviewer-administered survey in the United States, Canada, United Kingdom, Spain, Hong Kong, and mainland China. Generalized linear models were used to the effect on utilities of current health, age and sex, jurisdiction and, for infected respondents, current disease state. RESULTS: The sample included 534 CHB-infected patients and 600 uninfected respondents. CHB and compensated cirrhosis had a moderate impact on HRQOL with utilities ranging from 0.68 to 0.80. Decompensated cirrhosis and hepatocellular carcinoma had a stronger impact with utilities ranging from 0.35 to 0.41. Significant variation was observed between countries, with both types of respondents in mainland China and Hong Kong reporting systematically lower utilities. CONCLUSIONS: Health states related to CHB infection have substantial reductions in HRQOL and the utilities reported in this study provide valuable information for comparing new treatment options. The observed intercountry differences suggest that economic evaluations may benefit from country-specific utility estimates. The extent that systematic intercountry differences in utilities hold true for other infectious and chronic diseases remains an open question and has considerable implications for the proper conduct and interpretation of economic evaluations.
OBJECTIVES:Chronic hepatitis B (CHB) is a condition that results in substantial morbidity and mortality worldwide because of progressive liver damage. Investigators undertaking economic evaluations of new therapeutic agents require estimates of health-related quality of life (HRQOL). Recently, evidence has begun to accumulate that differences in cultural backgrounds have a quantifiable impact on perceptions of health. The objective was to elicit utilities for six health states that occur after infection with the hepatitis B virus from infected and uninfected respondents living in jurisdictions with low and with high CHB endemicity. METHODS: Standard gamble utilities were elicited from hepatitispatients and uninfected respondents using an interviewer-administered survey in the United States, Canada, United Kingdom, Spain, Hong Kong, and mainland China. Generalized linear models were used to the effect on utilities of current health, age and sex, jurisdiction and, for infected respondents, current disease state. RESULTS: The sample included 534 CHB-infectedpatients and 600 uninfected respondents. CHB and compensated cirrhosis had a moderate impact on HRQOL with utilities ranging from 0.68 to 0.80. Decompensated cirrhosis and hepatocellular carcinoma had a stronger impact with utilities ranging from 0.35 to 0.41. Significant variation was observed between countries, with both types of respondents in mainland China and Hong Kong reporting systematically lower utilities. CONCLUSIONS: Health states related to CHB infection have substantial reductions in HRQOL and the utilities reported in this study provide valuable information for comparing new treatment options. The observed intercountry differences suggest that economic evaluations may benefit from country-specific utility estimates. The extent that systematic intercountry differences in utilities hold true for other infectious and chronic diseases remains an open question and has considerable implications for the proper conduct and interpretation of economic evaluations.
Authors: Saskia Knies; Silvia M A A Evers; Math J J M Candel; Johan L Severens; André J H A Ament Journal: Pharmacoeconomics Date: 2009 Impact factor: 4.981
Authors: Weixia Ke; Chi Zhang; Li Liu; Yanhui Gao; Zhenjiang Yao; Xiaohua Ye; Shudong Zhou; Yi Yang Journal: Hepatol Int Date: 2016-06-07 Impact factor: 6.047
Authors: Caleb P Nelson; Jonathan C Routh; Tanya Logvinenko; Ilina Rosoklija; Paul J Kokorowski; Lisa A Prosser; Mark A Schuster Journal: J Pediatr Urol Date: 2015-04-30 Impact factor: 1.830
Authors: Kathleen M Beusterien; John Davies; Michael Leach; David Meiklejohn; Jessica L Grinspan; Alison O'Toole; Steve Bramham-Jones Journal: Health Qual Life Outcomes Date: 2010-05-18 Impact factor: 3.186
Authors: Elegance T P Lam; Cindy L K Lam; C L Lai; M F Yuen; Daniel Y T Fong; Thomas M K So Journal: Health Qual Life Outcomes Date: 2009-06-05 Impact factor: 3.186